Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
593 Results for "
Toxin
" in MedChemExpress (MCE) Product Catalog:
Products (593)
593 Results for "Toxin" in MCE Product Catalog:
Cat. No.: HY-P88031
Synonyms: ADPRT2, ADPRTL2, PARP2, Poly [ADP-ribose] polymerase 2, PARP-2, hPARP-2, ADP-ribosyltransferase diphtheria Toxin-like 2, DNA ADP-ribosyltransferase PARP2, NAD(+) ADP-ribosyltransferase 2, Poly[ADP-ribose] synthase 2, Protein poly-ADP-ribosyltransferase PARP2, ARTD2, ADPRT-2, pADPRT-2
Cat. No.: HY-178690
CAS No.: 1801552-15-7
Research Areas:
MyD88-IN-4 is a MyD88 inhibitor. MyD88-IN-4 exerts antiviral effects by up-regulating IFN-β, and anti-inflammatory effects by inhibiting pro-inflammatory cytokine production. MyD88-IN-4 prevents MyD88 homodimer formation and its interaction with IRF3/IRF7. MyD88-IN-4 demonstrates efficacy against encephalitic alphavirus infections by reducing viral replication and improving survival in VEEV TC-83-infected mouse models. MyD88-IN-4 can be used for the study of alphavirus infections, bacterial toxin-related diseases, and sepsis .
Cat. No.: HY-DY1108
CAS No.: 38806-38-1
Synonyms: ε-NAD (solution)
Research Areas:
Nicotinamide 1,N6-ethenoadenine dinucleotide (solution) (ε-NAD (solution)) is a fluorescent analog of NAD. Nicotinamide 1,N6-ethenoadenine dinucleotide can be cleaved by phosphodiesterase I (from C. adamanteus venom) and binds to bovine liver glutamate dehydrogenase. Nicotinamide 1,N6-ethenoadenine dinucleotide can serve as a substrate for G-ADP ribosylation of G proteins catalyzed by bacterial toxins. Nicotinamide 1,N6-ethenoadenine dinucleotide can be used as a fluorescent substrate for the study of ADP ribosylation reactions .
Solvent and concentration: ddH2O: 20 mM
Solvent and concentration: ddH2O: 20 mM
Cat. No.: HY-P992488
Synonyms: ZV0501 Antibody
Research Areas:
ZV05 (ZV0501 Antibody) is an anti-5T4 monoclonal antibody with an EC50 of 4.3 ng/mL against h5T4. ZV05 does not induce apoptosis or interfere with cell cycle progression. ZV05 accumulates specifically in 5T4-positive tumor xenografts. ZV05 can serve as the antibody component of antibody-active molecule conjugates (ADCs) to bind the 5T4 glycoprotein, thereby enabling targeted delivery of toxins. ZV05 is used in studies of 5T4-positive cancers, including triple-negative breast cancer .
Cat. No.: HY-134800
CAS No.: 692744-81-3
IBT21 is an endoplasmic reticulum stress inhibitor that binds to unfolded or misfolded proteins and prevents their aggregation. IBT21 inhibits UPR activation of the ATF6, IRE1 and PERK branches under ER stress, with IC50 values of 0.24 μM, 0.33 μM, and 0.46 μM, respectively. IBT21 protects cells from ER stress-induced death and mutant prion protein (protein toxin)-induced growth inhibition. IBT21 exhibits chemical chaperone activity distinct from UPR modulators, does not affect protein translation, moderately reduces DTT (HY-15917)-induced ER stress, and fails to inhibit the heat shock response. IBT21 is useful for research related to prion diseases .
Cat. No.: HY-149125
CAS No.: 71965-57-6
Synonyms: Ceramide trihexosides (porcine)
Target:
Research Areas:
Globotriaosylceramide porcine RBC (Ceramide trihexosides porcine) is a neutral glycosphingolipid belonging to the globoside series of erythrocytes, primarily isolated and extracted from porcine RBC. Globotriaosylceramide porcine RBC is a natural resistance factor against HIV-1 infection. Globotriaosylceramide porcine RBC blocks viral binding to CXCR4/CCR5 co-receptors through competitive binding to the V3 loop region of HIV-1 gp120, thereby inhibiting viral fusion and entry. Globotriaosylceramide porcine RBC is the major cell surface receptor for Shiga toxin. Globotriaosylceramide porcine RBC can be used for research on hemolytic uremic syndrome, HIV-1 infection, and Fabry disease .
Cat. No.: HY-185816
Research Areas:
TQB2102 is a bispecific epitope antibody-drug conjugate targeting HER2, composed of the antibody Rolditamig (HY-P992130) and the toxin molecule Deruxtecan-d2 (HY-13631ES3). TQB2102 binds to the ECD2 and ECD4 domains of HER2, promotes its own internalization by HER2-expressing cells, and delivers deuterated DXd payload to inhibit topoisomerase I. TQB2102 induces antibody-dependent cellular cytotoxicity, DNA damage, bystander killing activity, and inhibits cancer cell proliferation. TQB2102 can be used in research related to various cancers including metastatic breast cancer, colorectal cancer, and gastric/gastroesophageal junction adenocarcinoma .
Cat. No.: HY-N6799
CAS No.: 36519-25-2
Cat. No.: HY-W115727A
CAS No.: 9003-05-8
Synonyms: PAM,Anion,Mw 14-16 million
Cat. No.: HY-W115727B
CAS No.: 9003-05-8
Synonyms: PAM,Anion,Mw 18 million
Cat. No.: HY-P811793
Synonyms: ADPRTL1, KIAA0177, PARPL, PARP4, Protein mono-ADP-ribosyltransferase PARP4, 193 kDa vault protein, ADP-ribosyltransferase diphtheria Toxin-like 4, PARP-related/IalphaI-related H5/proline-rich, Poly [ADP-ribose] polymerase 4, Vault poly(ADP-ribose) polymerase, ARTD4, PH5P, PARP-4, VPARP
Cat. No.: HY-178219
CAS No.: 3103526-19-5
Research Areas:
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE contains a linker and bioactive small molecule toxins MMAE (HY-15162). Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE can conjugate with NN2101 (HY-P991293) (anti c-Kit) for synthesizing NN3201. NN3201 rapidly internalizes and inhibits SCF-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models, such as small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) .
Cat. No.: HY-P74608
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: RAC1; Ras-Like Protein TC25; Rac Family Small GTPase 1; Rho-Related GTP-Binding Protein RhoG; P21-Rac1; Pancreatic Ribonuclease; TC-25; Small Monomeric GTPase; Rac-1; MRD48; Ras-Related C3 Botulinum Toxin Substrate 1 (Rho Family, Small GTP Binding Protein
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P811793A
Synonyms: ADPRTL1, KIAA0177, PARPL, PARP4, Protein mono-ADP-ribosyltransferase PARP4, 193 kDa vault protein, ADP-ribosyltransferase diphtheria Toxin-like 4, PARP-related/IalphaI-related H5/proline-rich, Poly [ADP-ribose] polymerase 4, Vault poly(ADP-ribose) polymerase, ARTD4, PH5P, PARP-4, VPARP
Cat. No.: HY-138298B
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)
Target:
Research Areas:
Trastuzumab deruxtecan (DAR2) (T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 2. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Cat. No.: HY-138298C
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR4); DS-8201 (DAR4); DS-8201a (DAR4)
Target:
Research Areas:
Trastuzumab deruxtecan (DAR4) (T-DXd (DAR4); DS-8201 (DAR4); DS-8201a (DAR4)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 4. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Cat. No.: HY-138298D
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR6); DS-8201 (DAR6); DS-8201a (DAR6)
Target:
Research Areas:
Trastuzumab deruxtecan (DAR6) (T-DXd (DAR6); DS-8201 (DAR6); DS-8201a (DAR6)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 6. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Cat. No.: HY-N19899
CAS No.: 910050-51-0
Category:
Target:
Cat. No.: HY-N6799R
CAS No.: 36519-25-2
Category:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
